Home
About
Overview
Sharing Data
ORCID
Help
History (19)
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
A new way of relating: perceptions associated with a team-based error disclosure simulation intervention.
Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease.
Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities.
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities.
Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities. Cancer Cell. 2021 06 14; 39(6):730-733.
View in:
PubMed
subject areas
Genetic Variation
Genome-Wide Association Study
Healthcare Disparities
Humans
Medical Oncology
National Institutes of Health (U.S.)
Neoplasms
Pharmacogenetics
Precision Medicine
United States
authors with profiles
Olufunmilayo Olopade
Loren Saulsberry